Alembic Pharmaceuticals Limited will host a post-results conference call on Tuesday, August 4, 2026, at 5:30 PM IST to discuss its Q1 FY27 unaudited financial results. The session is restricted to analysts and institutional investors, providing a platform for management to address queries regarding the latest quarterly performance. This disclosure was filed with the Bombay Stock Exchange and the National Stock Exchange of India Ltd. on July 27, 2026.

Conference Call Details

The company's senior management team will lead the discussion. Investors and analysts have two options to join the call. The first option involves registering through the Diamond Pass portal, which provides dial-in numbers, passcodes, and pins directly to the registered email address. This method allows participants to connect without waiting for an operator. The second option involves direct dial-in using the universal access numbers or toll-free lines available for India, the USA, the UK, Singapore, and Hong Kong.

Dial-In Information

For further assistance, Isha Lamba can be contacted at +91 22-66951652 or via email at isha.lamba@alembic.co.in . The company's Chief Financial Officer, G. Krishnan, signed the disclosure letter dated July 27, 2026.

Alembic Pharmaceuticals announced on July 18, 2026, that its partner NATCO Pharma Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for Olaparib Tablets, 100 mg and 150 mg. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product Lynparza Tablets, 100 mg and 150 mg, of AstraZeneca Pharmaceuticals LP. This development allows Alembic to distribute the product in the U.S. market, while NATCO will handle the manufacturing of the tablets.

The Para IV litigation for the product is currently on-going. According to IQVIA data, Olaparib Tablets, 100 mg and 150 mg, have an estimated market size of approximately USD 1.4 billion in the U.S. for the twelve months ending March 2026. This market potential represents a significant commercial opportunity for the partnership.

Approval Details

The tentative approval covers the specific strengths of 100 mg and 150 mg. The product is indicated for the same uses as the reference listed drug. The distribution strategy involves Alembic managing the U.S. market supply chain, leveraging its established presence, while NATCO utilizes its manufacturing capabilities for production.

Regulatory Portfolio

With this latest tentative approval, Alembic has reached a cumulative total of 244 ANDA approvals from the USFDA. This portfolio consists of 224 final approvals and 20 tentative approvals. The company continues to expand its footprint in the complex generic market through such regulatory milestones.